| Schedule of summarizes the significant expenses |
| Schedule of summarizes the significant expenses | |
| | | |
| | | |
| | | |
| | |
| | |
Three months ended
March 31, | |
Six months ended
March 31, |
| | |
2026 | |
2025 | |
2026 | |
2025 |
| Research and development costs | |
| | | |
| | | |
| | | |
| | |
| Preclinical studies | |
$ | 31 | | |
$ | 104 | | |
$ | 33 | | |
$ | 416 | |
| Clinical trials | |
| 612 | | |
| 5,896 | | |
| 2,645 | | |
| 11,027 | |
| Personnel costs | |
| 3,470 | | |
| 3,010 | | |
| 5,122 | | |
| 6,674 | |
| Non-cash share-based compensation (recovery) | |
| (193 | ) | |
| 844 | | |
| 444 | | |
| 2,097 | |
| Other research and development costs(a) | |
| 272 | | |
| 38 | | |
| 605 | | |
| 124 | |
| Total research and development costs | |
| 4,192 | | |
| 9,892 | | |
| 8,849 | | |
| 20,338 | |
| | |
| | | |
| | | |
| | | |
| | |
| General and administrative costs | |
| | | |
| | | |
| | | |
| | |
| Personnel costs | |
| 583 | | |
| 371 | | |
| 1,040 | | |
| 1,146 | |
| Non-cash share-based compensation | |
| 507 | | |
| 605 | | |
| 977 | | |
| 1,406 | |
| Other general and administrative costs(b) | |
| 1,202 | | |
| 1,645 | | |
| 2,400 | | |
| 3,215 | |
| Total general and administrative costs | |
| 2,292 | | |
| 2,621 | | |
| 4,417 | | |
| 5,767 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other income | |
| 1,146 | | |
| 1,317 | | |
| 2,247 | | |
| 2,798 | |
| Net loss | |
$ | (5,338 | ) | |
$ | (11,196 | ) | |
$ | (11,019 | ) | |
$ | (23,307 | ) |
| a. | Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences,
and medical affairs strategy and branding. |
| b. | Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including
professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses. |
|